KDA GROUP ANNOUNCES PARTNERSHIP AGREEMENT WITH CHU DE QUÉBEC-UNIVERSITÉ LAVAL FOR THE DEPLOYMENT OF MEDHERIZE
MWN-AI** Summary
KDA Group Inc. has announced a partnership with the CHU de Québec–Université Laval to deploy its Medherize platform at Hôpital du Saint-Sacrement. This agreement focuses on enhancing care for breast cancer patients receiving complex oral treatments, facilitating better communication and coordination between healthcare teams and community pharmacists. Medherize is designed to ensure real-time therapeutic monitoring, leveraging data from Dossier Santé Québec and clinical protocols to automate management of adverse effects, improving efficiency in patient care.
Currently, Medherize supports breast oncology treatments, with plans to expand its use to other therapeutic areas, including biotherapies and treatments for autoimmune and rare genetic diseases. The partnership aligns with both KDA’s mission to provide innovative healthcare solutions and the CHU de Québec's vision of a patient-centered system that optimizes resource use and treatment follow-up.
KDA’s CEO, Marc Lemieux, emphasized that Medherize aims to enhance the quality of life for patients while aiding healthcare professionals in delivering personalized treatments. Patient testimonials, such as that of M. McNeil Caron, highlight the platform's user-friendliness and the peace of mind it provides regarding treatment management.
The partnership has already attracted interest from various stakeholders in the healthcare industry, including pharmaceutical companies and pharmacy chains, which suggests substantial growth potential for KDA's business model. As the platform expands, it is expected to significantly improve the management of specialty medications, showcasing the transformative potential of digital technology in modern healthcare systems.
KDA Group, recognized for its technological innovations in healthcare, anticipates that this collaboration will contribute to the broader goal of enhancing healthcare delivery both in Quebec and internationally.
MWN-AI** Analysis
KDA Group Inc. (TSXV: KDA) has recently announced a strategic partnership with the CHU de Québec-Université Laval, marking a significant advancement for both entities in the deployment of the Medherize platform. This collaboration aims to offer enhanced support to breast cancer patients undergoing intricate oral treatments and could serve as a template for expansion into other complex medical areas across Canada and beyond.
From an investment perspective, this partnership highlights KDA’s position as an innovator in healthcare technology and opens up promising avenues for growth. The Medherize platform, which integrates real-time therapeutic monitoring with clinical data from the provincial health dossier, has already received positive feedback from both healthcare professionals and patients, indicating strong user adoption prospects. This user-centric approach not only positions KDA favorably in the market but also sets the stage for broader applicability beyond oncology to include a range of specialty medications.
Considering the healthcare industry's increasing demand for digital and efficient solutions, KDA's capacity to streamline patient care and treatment management could translate into higher market share and revenue streams. Moreover, the interest from pharmaceutical companies and pharmacy chains to adopt Medherize suggests validation of KDA’s value proposition, which could drive further partnerships and collaboration opportunities.
However, investors should remain cautious. While the prospects are promising, there are inherent risks associated with the healthcare technology sector, including regulatory challenges and market competition. Hence, it may be prudent to monitor KDA’s execution of this partnership closely and watch for emerging financial metrics that would confirm its growth trajectory. Investors looking for opportunities in innovative healthcare solutions may find KDA Group a compelling option, especially as the company expands its impact in the evolving digital health landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Canada NewsWire
THETFORD MINES, QC, Dec. 3, 2025 /CNW/ - KDA Group Inc. (TSXV: KDA) ("KDA" or the "Corporation"), a leader in innovative technological solutions for healthcare professionals, is pleased to announce the signing of a partnership and collaboration agreement with the Centre hospitalier universitaire de Québec, Université Laval ("CHU de Québec") for the deployment of its Medherize platform at Hôpital du Saint-Sacrement, one of the CHU de Québec's five hospital facilities.
The Medherize platform is already implemented at Hôpital du Saint-Sacrement. This partnership aims to support breast cancer patients undergoing complex oral treatments, whose follow-up and coordination require close collaboration between hospital teams and community pharmacists. It will also serve as a springboard for expanding the solution to other hospital centers across Quebec, then throughout Canada, and eventually internationally.
Medherize enables real-time therapeutic monitoring through the integration of clinical data, including information from the Dossier Santé Québec (DSQ), and validated clinical protocols that automate the management of adverse effects. The platform provides care teams with a shared and continuous view of each patient's treatment journey, improving coordination and overall care efficiency.
The solution will soon extend beyond breast oncology to encompass a broader range of complex treatments and specialty medications, including biotherapies, additional oncology therapies, as well as treatments for autoimmune and rare genetic diseases.
"Our Medherize solution is designed to support healthcare professionals in delivering optimized and personalized treatments while enhancing patients' quality of life," said Marc Lemieux, Chief Executive Officer and Chairman of the Board of KDA.
Dr. Julien Clément, Director of Professional Services and Medical Affairs at the CHU de Québec, added:
"The implementation of Medherize within our institution could potentially allow our healthcare professionals to save time in treatment follow-up and optimize the use of our resources, to the direct benefit of our patients. Our assessment of this technology aligns with our vision of a more efficient healthcare system that is centered on patients' needs."
Ms. M. McNeil Caron, a patient treated at the CHU de Québec and user of Medherize, added: "The follow-up software allows me to easily and instantly access my lab results and other helpful advice. It's very user-friendly. I feel truly confident and well supported."
This partnership with the CHU de Québec has sparked strong interest within the healthcare industry. Several pharmaceutical companies, as well as pharmacy chains and independent pharmacists, have already expressed their intent to adopt or promote Medherize as previously disclosed by the Corporation in its press release dated December 1st, 2025, opening significant opportunities for KDA's business model.
Ultimately, the Medherize project will help improve patients' quality of life and support healthcare professionals by optimizing the management of specialty medications, a complex and critical aspect of modern healthcare.
ABOUT KDA GROUP
KDA Group is a leader in technological innovations and specialized software solutions (SaaS – Software as a Service) for the healthcare professionals' market. KDA is a corporation that offers high-quality products and has recognized and respected expertise among the various stakeholders in the pharmaceutical and medical sectors. The technology products developed by KDA aim, among other things, to accelerate the healthcare's digital transformation, and are available for the Canadian and international markets. Additional information about the Corporation is available at www.groupkda.com and on SEDAR+ at www.sedarplus.ca.
ABOUT THE CHU DE QUÉBEC–UNIVERSITÉ LAVAL
Bringing together Hôpital-Dieu de Québec, Hôpital Saint-François d'Assise, Hôpital du Saint-Sacrement, Hôpital de l'Enfant-Jésus, the CHUL and Centre mère-enfant Soleil, as well as the Administrative Centre and the Clinico-Logistical Platform, the CHU de Québec–Université Laval is the largest university hospital centre in Québec and one of the three largest in Canada. Providing general and specialized care, and especially highly specialized care, the CHU serves the population of all of eastern Québec and northwestern New Brunswick, representing a catchment area of nearly two million people. Closely affiliated with Université Laval and strongly oriented toward the future, it is a leading hub for university-level teaching in Québec. It also carries a research mission across numerous fields of excellence, technology assessment, evaluation of health intervention methods, innovation to help build the health system of tomorrow, and health promotion. The CHU employs approximately 18,900 people, including 12,608 staff members, 1,574 physicians, dentists and pharmacists, as well as 179 volunteers. Its Research Centre is one of the largest French-language medical research centers in North America, with an annual budget of $132.6 million, 1,138 researchers, 1,562 employees, and 1,234 students. www.chudequebec.ca
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release from KDA Group contains forward-looking statements. Forward-looking statements are typically identified by the words assumption, goal, guidance, objective, outlook, strategy, target, and other similar expressions, or future or conditional verbs such as aim, anticipate, believe, predict, could, expect, intend, may, plan, seek, should, strive, and will. By their nature, forward-looking statements require us to make estimates and assumptions and express opinions based on current conditions and anticipated developments, as well as other factors that Management may deem appropriate under the circumstances. There is inherent uncertainty and significant risk in these estimates, assumptions, and opinions, particularly of a commercial, economic, and competitive nature, and they are therefore subject to change. KDA Group cannot guarantee that these estimates, assumptions, and opinions will prove to be accurate.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
SOURCE KDA Group Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/December2025/03/c2097.html
FAQ**
How does the partnership between KDA Group Inc. KDA:CC and CHU de Québec align with their strategic goals for expanding the Medherize platform across Canada and internationally?
What specific improvements in patient care and resource management does KDA Group Inc. KDA:CC anticipate as a result of deploying Medherize at Hôpital du Saint-Sacrement?
Can KDA Group Inc. KDA:CC provide insights on how they plan to scale the Medherize solution beyond breast oncology to other therapeutic areas?
What measures will KDA Group Inc. KDA:CC implement to monitor the effectiveness of the Medherize platform in improving patient outcomes and healthcare efficiency?
**MWN-AI FAQ is based on asking OpenAI questions about Kda Group Inc. (TSXVC: KDA:CC).
NASDAQ: KDA:CC
KDA:CC Trading
-4.55% G/L:
$0.105 Last:
2,500 Volume:
$0.11 Open:
